Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319822 | 0.90 | IGF1R (0.50) | IGF1RKDRSYKCDK1MEN1 | |
| SCHEMBL6314422 | 0.88 | IGF1R (0.60) | IGF1RPIK3CGPIK3CAPIK3CBKDR | |
| SCHEMBL6321411 | 0.86 | NPC1 (0.49) | IGF1RSYKEGFRMEN1KMT2A | |
| SCHEMBL6314056 | 0.86 | IGF1R (0.52) | IGF1RPIK3CAKDRSYKMEN1 | |
| SCHEMBL6312065 | 0.84 | MAPT (0.45) | KDRSYKUSP2MEN1KMT2A | |
| SCHEMBL6312654 | 0.84 | CDK5 (0.46) | KDRSYKCDK5CDK5R1DYRK1A | |
| SCHEMBL6312589 | 0.84 | IGF1R (0.59) | IGF1RPIK3CGPIK3CAPIK3CBKDR | |
| SCHEMBL6311534 | 0.83 | NPC1 (0.46) | IGF1RKDRSYKEGFRABCG2 | |
| SCHEMBL6318179 | 0.82 | MERTK (0.46) | PIK3CGEGFRCDK1MEN1KMT2A | |
| SCHEMBL6319751 | 0.80 | IGF1R (0.43) | IGF1RSYKEGFRDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | IGF1R 4054/4885PIK3CG 1480/4885PIK3CA 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.